All In Biotech

Drug Trial Radar · NCT06594159

A Study of LY4065967 in Healthy Japanese Participants

A Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of LY4065967, to Evaluate the Effect of LY4065967 on the Pharmacokinetics of Rosuvastatin in Healthy Japanese Participants

Last checked: Nov 19, 2026Latest source record: Apr 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

59

Actual

Start

Oct 22, 2024

Primary completion

Mar 11, 2025

Study completion Mar 11, 2025

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to obtain safety and tolerability data of the study drug known as LY4065967 and rosuvastatin in healthy Japanese participants. Blood tests will be performed to check how much LY4065967 and rosuvastatin get into the bloodstream and how long it takes the body to eliminate it. This is a 3-part study and will last approximately 2 weeks excluding screening period for each part.

Conditions

  • Healthy

Interventions

  • LY4065967Drug

    Administered orally

  • PlaceboDrug

    Administered orally

  • RosuvastatinDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered to be Related to Study Drug AdministrationTime frame: Baseline to 7 Days
  2. Part B: Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered to be Related to Study Drug AdministrationTime frame: Baseline to 12 Days
  3. Part D: PK: Maximum Concentration (Cmax) of RosuvastatinTime frame: Predose on Day 1 Through 72 Hours Post-Dose
  4. Part D: PK: Area Under the Concentration Versus Time Curve (AUC) of RosuvastatinTime frame: Predose on Day 1 Through 72 Hours Post-Dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Souseikai Fukuoka Mirai Hospital

    Fukuoka, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.